Treatment after EVP in bladder cancer is undefined. Izalontamab brenitecan (HER2/3 TROP2 ADC) has good activity in bladder+lung cancer. A global randomised phase III has started enrolment 👉 Iza Bren alone vs platinum chemo in previously treated pts (including EVP). @OncoAlert

It was a pleasure to attend & present at the annual Portuguese urology conference in beautiful city of Porto on 25/10.Thanks for the invitation. #APU2025 ⁦@Uroweb⁩ ⁦@AStenzl⁩ ⁦⁦@JoanaMarinhOnc⁩ ⁦@drenriquegrande⁩ ⁦@JimCatto⁩ ⁦@sheffielduni⁩

💪 Nuevo consenso ACSM + ESSA Proponen una terminología común para describir la intensidad del ejercicio: ⚙️ muy baja · baja · moderada · alta · muy alta 🧭 esfuerzo: muy fácil → muy difícil https://t.co/BhqxBh0lPU

🚨 New in @LancetLongevity: Exercise prescriptions should be treated as first-line therapy in older adults—integrated with medication management to cut polypharmacy, boost function, and reduce adverse drug effects. 💡 Exercise is medicine, not an afterthought. 👉 Read here:

Wow! Not 1️⃣, not 2️⃣, but 3️⃣‼️@Nature papers concomitantly published during #ESMO25 @myESMO @LoiSher @adam_grippin @MDAndersonNews @PeterMacCC @NKI_nl @DrChoueiri @VanAllenLab @FAndreMD congrats to all authors and 🙏 for making this very unique session happen also @Nature ! 👇

A must-read review on non-clear cell RCC! @JCOOP_ASCO 👉 https://t.co/Ai1clNBHdT @ASCO #Cancer #Oncology @OncoAlert @PBarataMD

Great ESMO Guidelines session with @ArndtVogel & @LizzySmyth1 on #HCC. We discussed intermediate-stage challenges, 1L vs 2L decisions, and how national approvals & reimbursement shape real-world practice — still many questions to answer! #ESMO #LiverCancer #MyESMO 🇩🇪

In contrast to abiraterone, adding enzalutamide to ADT with RT in pts with high-risk localized prostate cancer did not improve survival outcomes! ENZARAD trial #ESMO25 @myESMO @DrYukselUrun @DrChoueiri @Silke_Gillessen @APCCC_Lugano @OncoAlert @dmukherji @neerajaiims

Terrific talk by @dmukherji #ESMO 👉Optimizing use of endocrine therapy and chemotherapy in mCRPC #prostatecancer 👉need to improve implementation of level-1 evidence, manage bone and CV toxicities & sequencing of therapy👇@OncoAlert @urotoday

KRAS G12D inhibitors work in #PDAC! More confirmatory data of this presented at #ESMO25 @myESMO I am so so happy to see these waterfall plots 😊 👉GFH375-VS7375 mono 👉HRS4642 with GemNabPaclitaxel Great discussion by #MaeveLowery KRAS - easy to test! 🥳🥳 #ESMOAmbassadors

PSMA Addition: A randomized phase 3 trial of ARPI +/- 177Lu-PSMA617 in mHSPC 1 PSMA+ PET/CT+ve HSPC showed ⬆️ PFS without OS at this stage (⬆️ cross over). Multiple 1st line options exist (E.g BRCA). Earlier treatment seems effective. Later trials achieved OS. #ESMO25 @OncoAlert

#ESMO25 Pegfilgrastim timing matters! In this randomized phase III trial (n=159, early-stage BC): Giving pegfilgrastim 72h after chemo — instead of 24–48h — cut bone pain by >50% without increasing neutropenia or FN risk.

💡Just released Practice changing study in NEJM👉 Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. PFS DV vs chemo (median, 13.1 vs. 6.5 months; Overall survival DV vs Chemo (31.5 vs. 16.9 months;) objective response was DV 76.1% (95% CI, 70.3

#BladderCancer #ESMO25 @OncoAlert coverage and @PGrivasMDPhD with the highlights from ✨Keynote 905 ✨DV + Toripalimab ✨IMvigor011 @wroclawski_uro @philippespiess @WbusatoJr @CSuartz @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala @anacardosomd

🎯 KEYNOTE-905 (EV-303): Setting a New Standard in Cisplatin-Ineligible MIBC! 💥 💊 Arms: 🔹 EV + Pembrolizumab (Perioperative) 🔹 RC + PLND (Control) 🧪 Population: Muscle-invasive bladder cancer (T2–T4aN0M0 / T1–T4aN1M0) 80% cisplatin-ineligible (Galsky criteria) 📊

Proud to have presented the academic international study #DISCUS at #ESMO25. An incredible collaboration between 🇬🇧UK, 🇫🇷France, and 🇪🇸Spain — proving that academic, investigator-initiated trials can be done and can deliver practice-changing messages in metastatic urothelial

LBA91 – AMPLITUDE Trial (PROs) #ESMO25 🧬 HRRm mHSPC: Niraparib + abiraterone + prednisone maintained baseline QoL while improving rPFS vs AA+P. ✅ No clinically meaningful HRQoL differences (FACT-P, EQ-5D-5L, BPI-SF). 📈 ≥94% PRO compliance; pts largely “not bothered” by side

Renal cancer 1st line randomised PII KMUA3B #ESMO25 with lenavatinib/pembro as the control (hard to beat with RR>80%). Len/pem/belzutifan showed good PFS (HR0.45) ✅ which may lead to a positive RIII (LS12) which is ongoing. TIGIT 🛑 & LAG3 🛑 were disappointing again @OncoAlert

The results of #POTOMAC trial are out in @TheLancet simultaneously released with #ESMO25 presentation @myESMO Happy to share our thoughts on this also out in the accompanying editorial. @SanRaffaeleMI @MyUniSR Front-line durvalumab and BCG in the treatment of

2420MO – STOPCAP Meta-analysis #ESMO25 📊 Pooled IPD from PEACE-1 & STAMPEDE: prostate RT in synchronous mHSPC. ⚖️ No overall OS benefit (HR 0.93, p=0.11) ✅ Low-volume benefit: HR 0.79 → +7.7% 5-yr OS ✅ ≤4 bone mets: HR 0.84 (+4.9%) ➡️ Benefit confined to low-volume,